title: [Synchronous programmed intensive therapy of patients with severe rheumatoid arthritis].
abstract: OBJECTIVE
  To evaluate efficiency and safety of intensive treatment program (synchroneous plasmapheresis, large-dose methotrexate and methypred) for patients with severe rheumatoid arthritis (RA).
  
  
  METHODS
  45 patients with highly active and progressive RA, systemic symptoms, corticosteroid dependence who had intolerance to standard therapy or had not responded to it were divided into 2 comparable groups. 25 patients of group 1 for a month got 6 plasmapheresis procedures with synchroneous intravenous injection of 40 mg of methotrexate and 250 mg of methypred. 20 patients of group 2 received pulse therapy with methypred (3 g) and methotrexate (200 mg). The intensive therapy was followed in all the patients with methotrexate in a dose 10-20 mg/week.
  
  
  RESULTS
  One, six and twelve months after treatment patients of group 1 demonstrated a decrease in RA clinical activity and inflammation. In a year remission by ACR criteria was achieved in one-third of the patients.
  
  
  CONCLUSIONS
  The sychroneous program of intensive therapy is highly effective in RA patients with vasculitis, ineffective standard therapy and corticosteroid dependence.
authors.forename: S K
authors.initials: SK
authors.lastname: Solov'ev
authors.forename: E A
authors.initials: EA
authors.lastname: Aseeva
authors.forename: A S
authors.initials: AS
authors.lastname: Chiklikchi
authors.forename: V A
authors.initials: VA
authors.lastname: Nasonova
mesh_terms: D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D010956:Plasmapheresis
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D008775:Methylprednisolone; D008727:Methotrexate